ClinicalTrials.gg
TerminatedNCT05139147Updated Aug 9, 2024

DAISe 1 Feasibility Study to Evaluate the DAISe Thrombectomy System for Acute Ischemic Stroke

An interventional study of DAISe Thrombectomy System in Acute Ischemic Stroke, sponsored by MIVI Neuroscience, Inc.. Terminated at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by MIVI Neuroscience, Inc. · Not applicable, Interventional, and Treatment

Why this study was terminated
Enrollment/Recruitment
Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study is a prospective, multi-center, single arm, feasibility study that will enroll a maximum of 36 subjects. The maximum enrollment is 10 subjects per site. A maximum of 6 investigational centers in Europe will participate. Enrollment is expected to take about 9 months, subject participation will last about 3 months.

02

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

03

In context

Ischemic Stroke

2,653 studies on the registry are indexed under Ischemic Stroke; 936 are open to participants now.

This study's enrollment of 16 is below the median of 120 across 1,799 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

MIVI Neuroscience, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Pre-stroke (24 hours prior to stroke onset) independent functional status in activities of daily living with modified Rankin Score 0-1. Patient must be living in their own home, apartment or seniors lodge where no nursing care is required.
  • Diagnosis of acute ischemic stroke and referred to interventional neuroradiology center for mechanical thrombectomy with study enrollment time planned within 8 hours from onset of symptoms.
  • Disabling stroke defined as a baseline NIHSS > 6.
  • Thrombolytic therapy (IV tPA) received within 4.5 hours of onset/ last known well according to prescribed dosing OR documented ineligibility for thrombolytic therapy.
  • Confirmed symptomatic, large vessel occlusion of the intracranial internal carotid artery, middle cerebral artery, M1, or M2 with mTICI 0-1.
  • The following baseline imaging criteria should be met: MRI criterion- volume of diffusion restriction visually assessed ≤50 mL OR ASPECTs score 5-10 or T criterion- ASPECTS 6-10 on imaging NE-CT, CTA and/or CTP available
  • Signed informed consent from patient or legal representative or if applicable, documented medical necessity for inclusion in a clinical study in an emergency followed by signed informed consent.
  • Patient is affiliated in the social security system.

Exclusion criteria

Exclusion Criteria:

  • Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of recent/ fresh hemorrhage on presentation.
  • Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic.
  • Rapidly improving neurological deficits based on the investigator's clinical judgement.
  • Pregnancy; if a woman is of child-bearing potential and urine or serum beta HCG test is positive.
  • Severe contrast allergy or absolute contraindication to iodinated contrast.
  • Renal failure (serum creatinine level ≥ 3 mg/dL or on dialysis).
  • Severe, sustained hypertension resistant to treatment (SBP >185 mmHg or DBP >110 mmHg).
  • Use of warfarin anticoagulation (or other applicable anti-vitamin k anticoagulants) with International Normalized Ratio (INR) > 3.0 at the time of the procedure or any known hemorrhagic or coagulation deficiency.
  • Use of a direct thrombin inhibitor within the last 48 hours; partial thromboplastin time (PTT) > 2.0 times the normal prior to procedure.
  • Cerebral vasculitis or evidence of active systemic infection.
  • Suspicion of aortic dissection, presumed septic embolus or suspicion of bacterial endocarditis.
  • Clinical symptoms suggestive of bilateral stroke or occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation).
  • Seizure due to stroke.
  • Difficult endovascular access, difficult aortic arch or severe neurovascular tortuosity that will result in an inability to deliver endovascular therapy.
  • Evidence of dissection in the carotid or target artery for treatment.
  • Presence of a carotid artery stenosis or occlusion requiring balloon angioplasty or stenting at time of the procedure.
  • A severe or fatal comorbid illness that will prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient.
  • Patient cannot undergo an MRI of the head due to MRI contraindication.
  • Patient is unable or unwilling complete follow up visits.
  • If before the stroke, the patient is under a legal protective measure, they will not be able to participate in the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    DAISe Thrombectomy System

    Mechanical thrombectomy utilizing the DAISe Thrombectomy System, consisting of the DAISe Thrombectomy Device and DAISe Delivery Catheter, used with aspiration.

    Device: DAISe Thrombectomy System

Interventions

  • DeviceDAISe Thrombectomy System

    DAISe Thrombectomy System for mechanical thrombectomy

06

What researchers measure

Primary outcomes

  1. Rate of first pass revascularization success

    First pass successful revascularization defined as mTICI (modified Treatment in Cerebral Ischemia) 2b-3 flow in the target vessel post-treatment with the DAISe Thrombectomy System used with aspiration.

    Time frame: procedure

  2. Rate of symptomatic intracranial hemorrhage

    Symptomatic intracranial haemorrhage at 24 (+/-12) hours post-procedure as detected by CT/MRI with clinical deterioration of an NIHSS change of greater than or equal to 4

    Time frame: 12-36 hours

Secondary outcomes

  1. Rate of successful revascularization with the DAISe Device

    Successful revascularization of mTICI 2c-3 as a result of the first attempt with the DAISe Thrombectomy Device

    Time frame: Procedure

  2. Rate of procedural final successful revascularization

    Successful revascularization of final mTICI 2b-3 at the end of the procedure

    Time frame: Procedure

  3. Rate of successful revascularization at procedure end

    Successful revascularization of final mTICI 2c-3 at the end of the procedure

    Time frame: Procedure

  4. Rate of successful device use

    Measured by the successful delivery and placement of the DAISe Device in the target artery

    Time frame: Procedure

  5. Procedure time

    Time from groin puncture to successful revascularization defined as final mTICI 2b-3 flow

    Time frame: Procedure

  6. Complications

    Rate of procedure and/or device related complications

    Time frame: Procedure

  7. Rate of ENT

    Rate of embolization to a new vascular territory (ENT) during procedure

    Time frame: Procedure

  8. Infarct volume

    Infarct volume in MRI (FLAIR/Diffusion Weighted Imaging \[DWI\] combined)

    Time frame: 12-36 hours

  9. Emboli

    Number of emboli outside of main infarct affected territory and outside the affected territory in high-resolution DWI

    Time frame: 12-36 hours

  10. Intracranial hemorrhage

    Occurrence of all intracranial hemorrhage using the Heidelberg Bleeding Classification

    Time frame: 12-36 hours

  11. Good functional outcome

    Good functional outcome measured by Modified Rankin Score (measured 0 completely functional to 6 deceased) of 0-2

    Time frame: 3 months

  12. Mortality Rate

    All cause mortality

    Time frame: 3 months

07

Study locations

6 sites
  • CHU Pellegrin
    Bordeaux, 33000, France
  • CHU Montpellier
    Montpellier, France
  • CHU Urbains
    Nancy, 54035, France
  • CHU Bicetre Paris
    Paris, 94270, France
  • Groupe Hospitalier Pitie-Salpetriere
    Paris, France
  • Hôpital Purpan
    Toulouse, 31059, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Jul 2023, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2021
First posted
Dec 1, 2021
StartActual
Jan 12, 2022
Primary completionActual
Jul 20, 2023
CompletionActual
Aug 4, 2023
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05139147
Lead sponsor
MIVI Neuroscience, Inc.
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
Jan 12, 2022
Primary completion
Jul 20, 2023
Completion
Aug 4, 2023
Last update
Aug 9, 2024

Study contacts

Christophe Cognard, MD, PhD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion